国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Chinadaily.com.cn
 
Go Adv Search

China's mums key to Nestle baby milk deal

Updated: 2012-04-25 11:19

(Agencies)

  Comments() Print Mail Large Medium  Small

LONDON/BEIJING - The rise of the middle-class Chinese working mothers helps explain why Nestle paid nearly $12 billion for Pfizer's baby food business and could leave rivals scrambling to catch up.

Across emerging markets, nowhere more than in China, women are increasingly keeping jobs after having children -- a big driving force behind 10 percent annual growth in the $30 billion a year baby food industry.

Foreign labels such as SMA, Promil and S-26 Gold, which Nestle will get with the Pfizer deal, have a definite edge. Nestle's products include Nan, Gerber, Lactogen and Nestogen, but are less well known in China.

Baby milk was the foundation of the world's biggest food company, established in 1866 when German pharmacist Henri Nestle introduced a substitute for mothers who could not breast-feed.

Paying more for the Pfizer unit than the $10 billion that analysts had expected, Nestle trumped a bid from Danone and Mead Johnson.

The Pfizer nutrition business has 85 percent of its sales in emerging markets, and a quarter of sales in China.

Fuelled by 16 million new births a year, annual growth rates for China's baby formula market have been as high as 20 percent over the last five years. The market is forecast to double to $16 billion by 2016.

"The key strategic attraction of the deal in our view is Pfizer's No 5 position in the Chinese infant formula market where despite being global No 1 player in infant formula, Nestle has a relatively weak presence," said analyst Robert Dickinson at brokers Citi.

The Swiss giant is already market leader in milk formula in Latin America, Africa and the Middle East. This brings it the No 1 spot in Asia with its presence outside China counted too.

Globally, Nestle's baby food market share will rise to 25 percent from 19 percent - although this is likely to fall slightly after sell-offs to ensure regulatory clearance. Mead has 16 percent, Danone 14 percent and Abbott Laboratories 12 percent.

Few options for competitors

The Nestle-Pfizer business in China would only have a combined 12 percent market share behind Mead's leading 16 percent and Danone on 14 percent, but that would still be a rise from 10th place and there may be room for expansion.

Analysts looking at China expect the number of middle class households to double to 100 million by 2015.

博乐市| 堆龙德庆县| 嘉祥县| 嵩明县| 温泉县| 江孜县| 仁怀市| 綦江县| 保康县| 芜湖市| 台安县| 合阳县| 衡山县| 木兰县| 达尔| 武宣县| 淅川县| 四子王旗| 南开区| 新兴县| 通州市| 日喀则市| 象州县| 鸡西市| 泾川县| 宿州市| 囊谦县| 平原县| 杂多县| 界首市| 福贡县| 安庆市| 大邑县| 南宫市| 秭归县| 南和县| 常山县| 子长县| 多伦县| 日照市| 白朗县|